Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings, Inc. reports clinical-stage oncology developments centered on LB-100, its proprietary first-in-class PP2A inhibitor. Recurring updates describe proof-of-concept work in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma, including combination studies with immunotherapy and other cancer-treatment approaches.
The company also issues news on its broader cancer-treatment platform, including Liora Technologies Europe, radiotherapy technology, patent coverage, trial-site and collaborator activity, capital raises, annual-report highlights, executive and board changes, and investor-conference participation. Its public updates frame LIXT as a clinical-stage pharmaceutical and med-tech issuer focused on new targets for cancer drug development.
LIXTE Biotechnology Holdings has initiated its first clinical trial in Spain to evaluate the effectiveness of LB-100 in enhancing the cytotoxic effects of chemotherapy for patients with advanced soft tissue sarcoma (ASTS). Conducted by the Spanish Sarcoma Research Group (GEIS), the trial will commence at Fundación Jiménez Díaz University Hospital in Madrid, with additional sites planned in Valencia and Barcelona.
The Phase 1b trial aims to identify the recommended phase 2 dose and will involve approximately 150 patients randomized to receive either doxorubicin alone or in combination with LB-100. Completion is expected within nine months, paving the way for a subsequent Phase 3 trial.
CEO John S. Kovach expressed optimism about assessing LB-100's potential in improving treatment outcomes for ASTS, emphasizing the critical need for effective therapies.
LIXTE Biotechnology Holdings announced a significant step in its Phase 1b clinical trial for LB-100, a first-in-class protein phosphatase 2A inhibitor, to enhance treatment for extensive stage small cell lung cancer (ED-SCLC).
The Sarah Cannon Research Institute (SCRI) at Tennessee Oncology will now participate in the trial, led by notable oncologists.
John S. Kovach, M.D., emphasized that SCRI's involvement will accelerate patient recruitment, potentially demonstrating LB-100's efficacy in improving treatment outcomes for this aggressive cancer.
LIXTE Biotechnology Holdings has reported new insights on its lead clinical compound, LB-100, demonstrating that deficiency in PP2A can enhance the efficacy of immune checkpoint blockers in cancer treatment. An article published in The Journal of Clinical Investigation outlines a previously unappreciated mechanism linking PP2A to immunosuppression in tumors. CEO John S. Kovach highlighted the potential of LB-100 in immunotherapy, particularly for extensive stage small cell lung cancer, where a clinical trial is currently recruiting participants. This study aims to evaluate LB-100's effectiveness in conjunction with chemotherapy and immune blockers.
LIXTE Biotechnology Holdings announced promising results from preclinical studies using its lead clinical compound LB-100, in combination with a WEE1 kinase inhibitor, showing remarkable effectiveness in killing cancer cells, particularly in tough cases like colorectal, pancreatic, and bile duct carcinomas.
Notably, when cancer cells developed resistance to this therapy, they lost their cancerous properties in animal models. This indicates a novel concept termed “tumor suppressive drug resistance”, suggesting that the resistance can lead to decreased oncogenic capacity. The findings present a potential breakthrough in cancer treatment, emphasizing the unique mechanism of LB-100.
LIXTE Biotechnology Holdings (Nasdaq:LIXT) will present at the Planet MicroCap Showcase: VIRTUAL 2022 investor conference on December 7, 2022, at 3:30 p.m. EST. John S. Kovach, M.D., founder and CEO, will lead the presentation and host a Q&A session.
The conference showcases LIXTE's lead compound, LB-100, a novel protein phosphatase inhibitor with potential in cancer therapy. Interested attendees can access the presentation via this webcast link.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) has gained authorization from the Spanish Agency for Medicines (AEMPS) for a Phase 1b/randomized Phase 2 study of LB-100, its lead compound, combined with doxorubicin for treating advanced soft tissue sarcomas (ASTS). This study aims to determine the efficacy and safety of the combination versus doxorubicin alone, which has been the standard treatment for over 40 years. With up to 170 patients expected, results may enhance treatment outcomes in this niche area, potentially changing existing protocols.
LIXTE Biotechnology Holdings, Inc. has appointed Bas van der Baan as an independent director to its Board of Directors. With over 20 years of experience in biotechnology, particularly in oncology, Mr. van der Baan is expected to enhance LIXTE's strategic direction, particularly in the commercialization of its first-in-class cancer drug, LB-100. This compound targets protein phosphatase 2A and aims to improve patient outcomes in chemotherapy and immunotherapy. LIXTE's novel approach is unique in the market and backed by a strong patent portfolio.
LIXTE Biotechnology Holdings has appointed Professor René Bernards as an independent director on its Board. Bernards, a renowned figure in cancer drug development, will leverage his expertise to guide the company as it advances its lead compound, LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor. This appointment follows Bernards' presentation of promising data on LB-100’s effectiveness alongside other anti-cancer treatments. LIXTE focuses on innovative cancer therapies, positioning itself strategically in the competitive pharmaceutical landscape.
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) has successfully closed a registered direct offering, raising $5.8 million through the issuance of 2,900,000 shares at $2.00 per share. The funds will be allocated for working capital and the clinical development of its lead compound, LB-100. The offering was facilitated by WestPark Capital, Inc. and WallachBeth Capital, LLC. The shares were offered pursuant to a previously filed 'shelf' registration statement with the SEC.
On April 14, 2022, WallachBeth Capital completed a registered direct offering for LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), selling 2,900,000 shares at $2.00 each, totaling $5.8 million in gross proceeds. The offering was facilitated by WallachBeth Capital and WestPark Capital. LIXTE is focused on cancer drug development and is advancing its lead compound, LB-100, which targets the PP2A protein. Initial clinical trials for LB-100 are underway, indicating its potential to enhance cancer therapy outcomes.